A B S T R AC T
Background. Obese sarcopenia characterized by increased fat mass and protein-energy wasting (PEW) is not uncommon in chronic kidney disease (CKD) stage 5 patients in whom it is associated with worse outcomes. Serum hepatocyte growth factor (HGF) is associated with obesity in the general population and is increased in CKD patients in whom its association with body composition is not known. We studied the associations between HGF, PEW and body composition, and between HGF and mortality, in CKD stage 5 patients starting dialysis.
Methods. In 224 CKD stage 5 patients (139 males, mean age 52 years, mean glomerular filtration rate (GFR) 6.6 mL/min), blood samples were obtained for analyses of HGF, high-sensitivity C-reactive protein (hsCRP), glucose, insulin and lipids. Total fat mass index (FMI), truncal fat mass index (TFMI) and lean body mass index (LBMI) assessed by dual-energy X-ray absorptiometry and PEW assessed by subjective global assessment (SGA) were recorded at baseline. Patients were followed up for 5 years. Results. Serum HGF levels were higher in patients with high TFMI versus low TFMI [3.1 (IQR: 2.4-4.5) versus 2.7 (IQR: 1.9-3.8) ng/mL; P = 0.01] and in those with PEW versus non-PEW [3.4 (IQR: 2.4-3.6) versus 2.8 (IQR: 2.1-3.8) ng/mL; P = 0.03]. Patients with both high TFMI and presence of PEW had significantly (P < 0.001) higher HGF concentration [4.4 (IQR: 3.3-6.6) ng/mL] than other patient groups (high TFMI and non-PEW, low TFMI and PEW or low TFMI and non-PEW). Multivariate linear regression showed that TFMI was an independent predictor of HGF (R 2 = 0.21, P = 0.048). In Cox analysis, patients with high HGF and presence of PEW had worse all-cause mortality after adjusting for age, gender and hsCRP (HR: 3.59, 95% CI: 1.19-5.35). Conclusions. Increased TFMI was an independent predictor of HGF in CKD stage 5 patients. Moreover, an elevated HGF level increased the mortality risk in the presence of PEW. These results suggest a central role of HGF in the metabolic and nutritional alterations in CKD stage 5 patients.
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I N T RO D U C T I O N
Obese sarcopenia, characterized by increased fat mass combined with protein-energy wasting (PEW) in chronic kidney disease (CKD) stage 5 patients, is not uncommon and is associated with worse outcomes [1] . Increasing fat mass, in particular truncal fat mass, producing and releasing numerous mediators including adipokines and cytokines, is associated with increased morbidity and mortality [2, 3] and inflammatory cytokines derived from adipose tissue may contribute to the development of PEW in CKD patients [4] while the impact on PEW and survival implications of other truncal fat-derived mediators are less known.
Hepatocyte growth factor (HGF) is a pleiotropic cytokine secreted by cells of mesenchymal origin such as adipocytes. An increased level of circulating HGF is associated with obesity in the general population [5] . Moreover, HGF has potent angiogenic and mitogenic effects and is implicated in liver disease, metabolic syndrome, cardiovascular disease and tumorigenesis [6] [7] [8] [9] . Also an elevated serum HGF level is associated with cardiovascular alterations such as left ventricular hypertrophy and increased intima media thickness, inflammation and predicts survival in CKD patients [10] [11] [12] [13] . However, the relationships between HGF and PEW, and between HGF and body composition including fat mass, have to the best of our knowledge not been studied previously in CKD patients.
In this study, we explored links between HGF and PEW (evaluated by subjective global assessment; SGA) and body composition parameters, including body fat compartments as well as its relation with mortality in CKD stage 5 patients starting on dialysis.
PAT I E N T S A N D M E T H O D S
Study design and patients Two hundred and twenty-four CKD stage 5 patients [139 males, mean age of 52 ± 12 years and glomerular filtration rate (GFR) of 6.6 ± 2.2 mL/min] who had been enrolled at the Karolinska University Hospital Huddinge from December 1994 to August 2006 were investigated close to the start of renal replacement therapy and were then followed up for 5 years. Patients were followed up until death or to the end of the study; for survival analysis, patients were censored at transplantation. Patients with clinical signs of acute infection, acute vasculitis or liver disease at the time of evaluation, or unwillingness to participate in the study were excluded. At the beginning of the study, all patients were interviewed to obtain data on demographics and clinical characteristics and underwent measurements of body composition, anthropometrics and laboratory parameters. The Ethics Committee of the Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden approved the study protocol and informed consent was obtained from all patients.
Among the 224 patients, 44 patients had already started on hemodialysis before the investigation. As using heparin is known to increase serum HGF level in hemodialysis patients [14] , we analyzed whether patients who had one or more dialysis sessions before the investigation differed with regard to HGF. However, HGF levels, measured before the hemodialysis session, did not differ between the patients who had been exposed to hemodialysis for a short time (<3 months) and those who had not yet received dialysis (P = 0.40); therefore, all 224 patients were included in the study.
Patients were classified on the basis of both HGF levels and the presence of PEW (SGA > 1). Low HGF group (≤2.9 ng/ mL) and high HGF group (>2.9 ng/mL) were defined according to the median of serum HGF levels. Eight patients did not have complete SGA data. Thus, the main part of the study involved a total of 216 patients who were divided into four groups: high HGF and PEW, high HGF and non-PEW, low HGF and PEW, and low HGF and non-PEW group, respectively.
A N T H RO PO M E T R I C E VA L U AT I O N A N D P E W
Patients underwent assessment of body composition, nutritional status and body mass index (BMI; defined as the body weight in kilograms divided by the square of patient height in meters). Body composition, including lean body mass (LBM) and total fat mass and truncal fat mass, were evaluated by dual-energy X-ray absorptiometry (DXA) using Lunar software version 3.4 (Lunar Corp., Madison, WI, USA). With this technique, fat mass and LBM distribution are directly
H G F a s s o c i a t e d w i t h T F M I a n d P E W estimated without making assumptions about the two-compartment model. The CV for the DXA measurement is 2.0 ± 0.7%. Total fat mass index (FMI), truncal fat mass index (TFMI) and LBM index (LBMI) were calculated according to the method of Kyle et al. [15] and expressed as kg/m 2 . PEW was evaluated by SGA [16] . SGA includes six different components: three subjective assessments that are performed by the patients (concerning the patient's history of weight loss, incidence of anorexia and incidence of vomiting) and three assessments performed by the evaluators (subjective grading of muscle wasting, the presence of edema and the loss of subcutaneous fat). On the basis of these assessments, each patient received a nutritional status score: (1) normal nutritional status, (2) mild malnutrition, (3) moderate malnutrition and (4) severe malnutrition. For the purposes of the current study, malnutrition was defined as an SGA score > 1.
B I O C H E M I CA L M E T H O D S
After an overnight fast, venous blood samples were taken for analyses. The plasma and serum samples were kept frozen at -70°C if not analyzed immediately. The GFR in these incident CKD stage 5 patients was calculated by the mean of renal urea and creatinine clearances from a 24-h urine collection. Serum HGF was analyzed using a solid-phase high-sensitivity photometric enzyme-linked immunosorbent assay (ELISA) kit (R&D System, Inc., Minneapolis, MN, USA). A specific radioimmunoassay kit was used to analyze plasma insulin (Pharmacia, Uppsala, Sweden). High-sensitivity C-reactive protein (hsCRP) was measured by the nephelometry method. ELISA commercial kits were also used for analyses of interleukin-6 (IL-6) (Roche Diagnostics GmbH, Penzberg, Germany) and soluble intracellular adhesion molecule-1 (ICAM-1) (R&D System, Inc., Minneapolis, MN, USA). Serum cholesterol, high-density lipoprotein cholesterol and triglycerides were analyzed by standard enzymatic procedures (Boehringer Mannheim, Mannheim, Germany). Low-density lipoprotein (LDL) cholesterol was calculated according to the Friedewald formula [17] . The remaining biochemical analyses were done using routine methods at the Department of Clinical Chemistry at Karolinska University Hospital at Huddinge.
S TAT I S T I CA L A N A LY S E S
All values are expressed as mean ± standard deviation (SD) or median [inter-quartile range(IQR)] or percentage, as appropriate. A P-value < 0.05 was considered to be statistically significant. The generalized linear model (GLM) procedure with least-squares means was used to identify significant interactions between HGF groups and presence of PEW. Comparisons of nominal variables between groups were made by a Chi-square test. Differences between the two groups were analyzed by Mann-Whitney's U test. Spearman's rank correlation was used to determine correlations between two variables. As HGF had a skewed distribution, we based on log-transformed data in multivariate linear regression analysis. Multivariate linear regression analysis was used to assess the relationship between serum log HGF and 1 SD of LBMI, 1 SD of FMI and 1 SD of TFMI, respectively, adjusting as well for age, gender, cardiovascular disease (CVD), SGA, and concentrations of LDL-cholesterol, insulin and hsCRP. Survival analysis was done with the Cox proportional hazard model among the four groups mentioned above. The group of patients with low HGF levels and non-PEW served as the reference category. Cox-regression analyses are presented as the hazard ratio [HR; 95% confidence intervals (CI)] adjusted for age, gender and hsCRP. The statistical analysis was performed using statistical software SAS version 9.3 (SAS Campus Drive, Cary, NC, USA).
R E S U LT S

Baseline characteristics
The median level of HGF was 2.9 (IQR: 2.2-4.3) ng/mL. Basal clinical characteristics and body composition data of the 216 CKD stage 5 patients, placed into four groups according to the median of HGF level and presence of PEW, are given in Table 1 . Both presence of PEW and serum HGF levels positively associated with the presence of CVD, higher age, higher levels of BMI, FMI, TFMI and inflammatory markers (hsCRP and IL-6), and lower albumin levels, and for CVD there was a significant interaction of PEW and HGF in relation to the presence of CVD.
When separating the patients according to the presence of PEW, patients with PEW had a higher HGF level compared with non-PEW patients [3.4 (IQR: 2.4-3.6) (n = 66) versus 2.8 (IQR: 2.1-3.8) (n = 150) ng/mL; P = 0.03]. According to the median of TFMI, patients with high TFMI (TFMI > 3.8 kg/ m 2 ) had significantly elevated HGF levels when compared with low TFMI patients [3.1 (IQR: 2.4-4.5) (n = 112) versus 2.7 (IQR: 1.9-3.8) (n = 112) ng/mL; P = 0.01].
When further separating the patients according to both median of TFMI values (TFMI > 3.8 kg/m 2 ) and the presence of PEW, those patients with high TFMI who had signs of PEW had a significantly higher HGF concentration [4.4 (IQR: 3.3-6.6) ng/mL; n = 26] than patients in the other three groups, i.e. high TFMI and non-PEW [2.9 (IQR: 2.3-4.0) ng/mL; n = 82], low TFMI and the presence of PEW [2.6 (IQR: 2.0-3.7) ng/mL; n = 40] and low TFMI and non-PEW group [2.7 (IQR: 1.9-3.5) ng/mL; n = 67] (P < 0.001), respectively.
Spearman's rank correlation matrix for serum HGF level and other variables A correlation matrix, presenting Spearman's rank correlation was used to determine correlations between serum HGF, body composition and other variables ( Table 2) . HGF was associated positively with age (rho = 0.29; P < 0.001), the presence of CVD (rho = 0.17; P = 0.01) and PEW (rho = 0.15; P = 0.03), BMI (rho = 0.15; P = 0.03), FMI (rho = 0.17; P = 0.01), TFMI (rho = 0.21; P = 0.002; see Figure 1 ), insulin (rho = 0.18; P = 0.01), LDL-cholesterol (rho = 0.19; P = 0.01), hsCRP (rho = 0.44; P < 0.001), ICAM-1 (rho = 0.24; P < 0.001), and inversely with serum albumin (rho = -0.16; P = 0.02). 
O R I G I N A L A R T I C L E H G F a s s o c i a t e d w i t h T F M I a n d P E W
There were no significant relationships between HGF and gender, diabetes, LBMI and GFR and also (data not shown) no associations with circulating levels of creatinine, glucose, total cholesterol and triglycerides.
Multivariate linear regression analysis of FMI, TFMI and LBMI as predictors of HGF
The association between HGF and body composition was further analyzed using multivariate linear regression models of serum log of HGF and 1 SD of FMI, TFMI, and LBMI, respectively (Table 3) . In crude analysis and in Model 1, adjusting for age and gender, HGF was associated with FMI and TFMI, but not with LBMI. In Model 2, adjusting also for CVD and SGA, the associations with HGF remained significant (FMI, R 2 = 0.12, P = 0.004; TFMI, R 2 = 0.12, P = 0.002). Finally, we analyzed whether the observed alterations in lipid and glucose metabolism, and inflammation, influenced the relationship between serum HGF versus LBMI, FMI and TFMI. Thus, in Model 3, following adjustments also for serum LDLcholesterol, insulin and hsCRP, only TFMI remained related to HGF levels (R 2 = 0.21, P = 0.048).
Survival analysis
During a median follow-up period of 41.6 (IQR: 22.2-60.8) months, 61 patients died, and 74 patients underwent renal transplantation. In a multivariate Cox proportional model, patients with PEW and high (HR: 5.02, 95% CI: 2.53-9.95) or low (HR: 2.76, 95% CI: 1.19-6.39) HGF levels had increased mortality risk but not in non-PEW patients with high HGF levels compared with non-PEW patients with low HGF levels. However, after adjusting for age, gender and hsCRP, the relationship only remained significant in patients with high HGF and the presence of PEW (HR: 3.59, 95% CI: 1.19-5.35) ( Table 4 ). In contrast, in a Cox proportional hazards model, 
F I G U R E 1 :
Relations between serum hepatocyte growth factor (HGF) and truncal fat mass index (TFMI) in 224 CKD stage 5 patients starting on dialysis. HGF, hepatocyte growth factor; hsCRP, high-sensitivity C-reactive protein; HR, hazard ratio; NS, no significance; PEW, protein-energy wasting; 95% CI, 95% confidence interval.
O R I G I N A L A R T I C L E
H G F a s s o c i a t e d w i t h T F M I a n d P E W using the continuous value of HGF, the all-cause mortality risk of a high HGF level was significantly related to mortality in a crude model (HR: 1.13, 95% CI: 1.02-1.26); however, this association lost its statistical significance after adjusting for age and gender (HR: 1.06, 95% CI: 0.93-1.21).
D I S C U S S I O N
To the best of our knowledge, this is the first study investigating the relationship between the level of serum HGF in relation to the presence of PEW and body composition, in particular fat mass, in CKD stage 5 patients starting on dialysis. We demonstrated that patients with high TFMI and the presence of PEW had higher serum HGF levels, and that a high HGF level was associated with FMI and TFMI. After multiple adjustments, only TFMI remained as an independent predictor of HGF. Moreover, in the presence of PEW, an elevated HGF level was associated with an increased all-cause mortality risk in CKD stage 5 patients.
The observed associations between HGF, markers of glucose-insulin system and lipid metabolism and several nutritional markers suggest that HGF may have a central role in the metabolic and nutritional alterations of end-stage renal disease patients. However, the observed associations between HGF and the presence of PEW (defined as poor nutritional status as assessed by SGA score > 1), body composition indices (BMI, FMI, TFMI, but interestingly not LBMI) and serum albumin are difficult to interpret as these markers may be linked to inflammation which in turn is associated with HGF [13] . For example, serum albumin-which was not dramatically different between the four groups presented in Table 1 -may be more strongly linked to inflammation than to a poor nutritional status [18] . The current finding that HGF was more related to an increased fat mass than to reduced muscle protein stores as assessed by the LBMI (but related to other indices of poor nutritional status in the current study) is in line with the concept that fat stores tend to be underutilized in PEW [19] .
In the present study, serum HGF levels were also associated with higher age; considering that higher age is usually accompanied by higher prevalence of comorbidities including CVD and PEW and higher circulating concentrations of several inflammation markers, one may speculate that inflammation could be the common pathway linking HGF with higher age. This is supported by some studies showing that inflammatory cytokine stimulation induces up-regulation of HGF [20, 21] . In the current study, inflammation was more marked with increasing age, and inflammation was associated with HGF; this might explain why HGF levels increased with increasing age in our cohort. Furthermore, inflammation is also related to PEW [22] and with signs of CVD, such as increased intima media thickness, arterial remodeling and left ventricular hypertrophy [10, 13] , complications which are more common in elderly CKD patients.
A novel finding of this study is that HGF was positively associated with truncal fat mass even after multiple adjustments (age, gender, CVD, SGA and markers reflecting inflammation and alterations in lipid and glucose metabolism), whereas total FMI lost its significance as a predictor of HGF after these adjustments. Adipose tissue is thought to be the largest endocrine organ in the body, and adiposity has been shown to be a major contributor to plasma HGF in obese non-renal subjects [23] . An in vitro study also shows that the 3T3-L1 adipocyte cell line can secrete HGF [24] , confirming that adipocytes synthesize and secrete HGF. The distribution of fat, in particular truncal fat mass, influences the metabolic implications of adiposity such as hyperadipokinemia, dyslipidemia, oxidative stress, release of inflammatory mediators and PEW [2, [25] [26] [27] . Thus, as truncal fat mass is biologically more active than nontruncal fat mass, this may explain why truncal fat mass fat is more closely associated with increased morbidity than nontruncal fat mass [28] . We therefore speculate that adipocytes in truncal fat were a main source of HGF, which could explain the positive association between serum HGF level and TFMI in the current study. Furthermore, inflammation, which is highly prevalent in CKD patients and a known predictor of HGF in dialysis patients [13] , stimulates the secretion of HGF [20, 21] and truncal fat mass releases two to three times the amount of inflammatory cytokines than does non-truncal fat mass [29] . However, pro-inflammatory cytokines derived from fat mass are thought to be secreted from activated macrophages invading the adipose tissue, whereas HGF derived from fat mass is produced by adipocytes [30] . This may be the reason why HGF was independently associated with TFMI even following adjustment for inflammation (as assessed by hsCRP).
Notably, it is interesting that patients with high TFMI and concomitant PEW presented with the highest HGF levels. This indicates that CKD stage 5 patients with obese sarcopenia, characterized by the presence of PEW despite increased fat mass [1] , have especially high HGF levels. This observation implicating obese sarcopenia as a condition linked to HGF is a main novel finding of our study. Furthermore, our findings that HGF in the presence of PEW was associated with increased mortality and that HGF was associated with abdominal obesity are in general agreement with previous observations that abdominal obesity, especially when combined with indices reflecting poor nutritional status, is associated with increased mortality in end-stage renal disease patients [31] . It is well established that the presence of PEW is linked with uremia per se, presence of inflammation and co-morbidity, conditions which are associated with an increased risk of mortality in end-stage renal disease patients [32, 33] . In the current study, whereas patients with the presence of PEW had a higher all-cause mortality risk than well-nourished patients, the mortality risk was amplified by a high HGF level, and this effect was independent of inflammation, corroborating results by Malatino et al. in hemodialysis patients [13] . On the other hand, inflammation is thought to contribute substantially to the high mortality in CKD patients and, in the current study, hsCRP (as well as IL-6; data not shown) correlated with serum HGF concentrations. It should be noted, however, that HGF attenuates the inflammatory response through inhibition of the NF-κB pathway [34, 35] and, by suppression of inflammation, HGF can protect one from oxidative damage [36] .
Through these functions, it has been shown that HGF plays an important role in ameliorating acute and chronic injury of multiple organs [37, 38] . Thus, the finding that HGF concentration predicts mortality may reflect its self-protective role. Further studies with repeated measurements of HGF, markers of inflammation and endothelial dysfunction, and monitoring of CVD events, are needed to explore whether HGF could counteract the harmful effects of inflammation in CKD stage 5 patients.
There are certain limitations that should be taken into account when interpreting the results of the current study. First, this is a post hoc analysis which precludes conclusions regarding causality. Second, we rely on only one single measurement of HGF and PEW at the baseline; conceivably, both parameters may be influenced by the dialysis time and modality during the 5-year follow-up period. Third, the results regarding the association between HGF and mortality should be interpreted with caution: whereas the all-cause mortality risk of a high HGF level was significantly related to mortality in a crude model similar to a previous study [13] , this association lost its statistical significance after adjusting for age and gender, whereas, in adjusted models, the association between HGF and mortality was significant only in the presence of PEW. Finally, the results of this study raises several intriguing questions regarding the potentially protective and counteracting impact of HGF in incident dialysis patients. Further studies are needed to assess the complex roles of HGF as, on the one hand, a potential protective factor and, on the other hand, a factor associated with obese sarcopenia, with links to truncal adiposity and uremic complications such as PEW and inflammation.
In conclusion, in this, the first study investigating the relationship between HGF, presence of PEW and body composition in CKD stage 5 patients, the results suggest a central role of HGF in the metabolic and nutritional alterations in CKD stage 5 patients and that this effect is primarily linked to the metabolically active truncal fat mass. 
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